Michael Birrer, MD, PhD

Panelists share closing thoughts and practice pearls, emphasizing the importance of staying updated on emerging therapies, utilizing biomarkers for personalized treatment, and maintaining open communication with patients to ensure tailored and effective care in managing advanced cancers.

Panelists discuss how future therapies, such as antibody-drug conjugates (ADCs) and novel combination therapies, could enhance immuno-oncology (IO) sequencing by offering more targeted options for patients who have progressed on initial IO therapies, while addressing resistance mechanisms and improving overall treatment outcomes.

Panelists discuss how biomarker testing, including microsatellite instability (MSI), tumor mutational burden (TMB), and HER2, plays a crucial role in guiding treatment decisions for advanced and recurrent endometrial cancer (EC), both in initial immunotherapy selection and in shaping post-immunotherapy therapy strategies.

Panelists discuss how integrating immuno-oncology (IO) sequencing into treatment algorithms requires clear, evidence-based guidelines, refined patient selection based on biomarkers, multidisciplinary decision-making, and ongoing clinician education to optimize its use and ensure more informed, consistent treatment decisions.

Panelists discuss how community oncologists should focus on personalized treatment plans that incorporate the latest clinical evidence, while also addressing challenges such as insurance approval processes, treatment costs, and the importance of effective communication with patients and multidisciplinary teams to optimize care and overcome barriers.

Panelists discuss how considering a patient's quality of life (QOL)—including treatment adverse effects, functional status, mental health, and the burden of care—is essential in making treatment decisions, with shared decision-making ensuring that therapeutic choices align with the patient's values and QOL priorities.

Panelists discuss how improving patient selection for immuno-oncology (IO) sequencing through refined biomarkers, comprehensive genetic profiling, and consideration of patient health and treatment history can optimize treatment strategies and enhance outcomes by tailoring therapies to the right patients at the right time.

Panelists discuss how gaps in treatment options for advanced endometrial cancer (EC) following immuno-oncology (IO) therapy, including a lack of effective post-IO therapies, limited understanding of optimal sequencing, and the need for targeted therapies and improved biomarkers, highlight the ongoing challenges in personalizing treatment and managing adverse effects in this patient population.

Panelists discuss how studies providing real-world data or large-scale randomized controlled trials (RCTs) on immuno-oncology (IO) sequencing, along with ongoing clinical trials in advanced endometrial cancer (EC), could drive changes in clinical practice by improving survival outcomes, refining patient selection, and informing treatment sequencing to enhance patient management strategies.

Physicians discuss how recent studies have influenced their clinical practice, leading to updates in diagnostic strategies, treatment protocols, and patient communication, with a focus on evidence-based decision-making, refined therapeutic choices, and personalized care to improve patient outcomes.

Panelists discuss how recent studies highlight the potential of second-line immunotherapy approaches, including the pembrolizumab-lenvatinib combination and re-challenging with second-line immunotherapy, to improve outcomes in advanced endometrial cancer (EC), with an emphasis on biomarker-driven strategies, careful monitoring for toxicity, and the need for further research to optimize treatment sequencing and patient selection.

Panelists discuss how the pembrolizumab-lenvatinib combination offers promising efficacy as a second-line therapy for patients with mismatch repair deficiency (dMMR) endometrial cancer (EC) who did not respond to pembrolizumab monotherapy, with an emphasis on biomarker-driven treatment decisions, managing toxicity, and the need for further studies to refine patient selection and treatment strategies.

Panelists discuss how real-world studies on immune checkpoint inhibitors (ICIs) in advanced or recurrent endometrial cancer (EC) provide valuable insights into treatment effectiveness, patient outcomes, and the management of adverse events, helping refine treatment strategies, especially for biomarker-driven therapy.

Panelists discuss how a patient's prior treatment history, including response to previous therapies, toxicity, biomarker status, and clinical trial participation, plays a critical role in determining subsequent therapy for advanced endometrial cancer (EC).

Panelists discuss how treatment decisions for advanced endometrial cancer (EC) patients after progressing on immune-oncology (IO) therapy are guided by clinical trial data, real-world evidence, biomarker status, initial therapy response, and patient-specific factors to personalize subsequent treatment strategies.

Panelists discuss how the decision to continue or discontinue immune-oncology (IO) therapy in subsequent lines of treatment for advanced endometrial cancer (EC) is influenced by factors such as tumor response, biomarker status, treatment tolerability, patient health, and the availability of alternative therapies.

Panelists discuss how treating patients with advanced endometrial cancer (EC) who progress after immune-oncology (IO)-chemotherapy involves reassessing tumor biomarkers, considering alternative immunotherapies or targeted treatments, and personalizing care based on prior treatment responses and individual patient factors.

Panelists discuss how the integration of immunotherapy, particularly immune checkpoint inhibitors (ICIs) and combination therapies, is transforming the treatment landscape of advanced endometrial cancer (EC), with a focus on biomarker-driven approaches and the ongoing role of chemotherapy.

Michael J. Birrer, MD, PhD, discusses how the expansion of antibody-drug conjugates can address the need for more effective regimens in platinum-resistant ovarian cancer.

Michael J. Birrer, MD, PhD, discussed remaining questions when addressing platinum-sensitive ovarian cancer.

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the prevalence of cervical cancer in the United States.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the challenges associated with the patient demographics of cervical cancer.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses patient preferences for cervical cancer treatment, as well as the demographics of this population.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the FDA approval of rucaparib for as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the novel treatment options that could be explored in the future treatment of patients with cervical cancer.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the remaining challenges in treating patients with cervical cancer.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses recent advancements in cervical cancer.